• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Warburg Pincus completes acquisition of Bausch & Lomb

Article

New York-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.

New York

-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.  

“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for [B&L] and advance our leadership in the eye health industry,” said Ronald L. Zarrella, chairman and chief executive officer of B&L, Rochester, NY.
 
Elizabeth H. Weatherman, a Warburg Pincus managing director, said, “We look forward to helping the company build upon its rich heritage and premier brand in ophthalmology.”

B&L stock has been delisted on the New York Stock Exchange. Under the terms of the acquisition agreement, B&L shareholders are entitled to receive $65 in cash for each share of B&L common stock that they hold.

 

Related Videos
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.